Inhibikase Therapeutics, Inc. (IKT)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$49.6M
Cash & Equivalents
$12.1M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$269M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07365332 An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) PHASE3 Recruiting 486

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IKT.

SEC EDGAR Filings

All SEC filings for Inhibikase Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.